

- resorption of
 biochemical markers of, 2494–2495
 estrogen status and, 2491–2492, 2492f
 mechanism of, 2489–2490, 2491f
 structure of, 2454
- Bone age, 2257
- Bone-anchored hearing aid, 223
- Bone-conduction threshold, 222
- Bone disease
 anaerobic bacterial infections, 1099–1100
 in chronic kidney disease, 1815
 in cirrhosis, 2067
 with defective mineralization, 426e-5–6
 dysplasias, 426e-7
 extraskelatal calcification and ossification, 426e-7–8
 fibrous dysplasia, 426e-6, 426e-6f
 in Gaucher disease, 432e-5
 in IBD, 1958
 metastases from other sites, 102e-10–11, **119e-4**
 in multiple myeloma. *See* Multiple myeloma, clinical features of
 in osteogenesis imperfecta, 2508
 Paget's disease. *See* Paget's disease of bone
 primary immunodeficiencies with, 375e-2
 sarcoma. *See* Bone sarcoma
 sclerosing, 426e-4–5
 in tuberculosis, 1110–1111
- Bone loss. *See* Osteoporosis
- Bone marrow/bone marrow examination
 in anemia, 397
 in aplastic anemia, 81e-7f, 665f, 666
 cellularity in, 81e-7f, 663t
 in CML, 689, 689t
 collection for transplantation, 139e-1
 differential diagnosis of "dry tap," 135e-2t
 erythroid hyperplasia in, 81e-8f, 397f
 hypocellular, 663t
 iron stores, 81e-8f, 628, 628t
 in megaloblastic anemia, 643, 644f
 in myelodysplastic syndromes, 668f, 670–671
 in myelofibrosis, 675, 675f. *See also* Primary myelofibrosis
 myeloid hyperplasia in, 81e-8f, 397f
 normal, 81e-7f, 397f
 in sarcoidosis, 2208
 stem cell niche sites in, 89e-2
- Bone marrow failure, **662**
 in aplastic anemia. *See* Aplastic anemia
 bleeding tendencies in, 404
 differential diagnosis of, 663t
 in eosinophilic fasciitis, 376, 664
 pathognomic cells in, 668f
- Bone marrow transplantation. *See* Hematopoietic stem cell transplantation
- Bone mass/strength
 aging and, 71
 gut microbiota and, 86e-7
 in IBD, 1958
 measurement of, 2493, 2493f, 2493t
 sex differences in, 6e-4
- Bone pain
 at end of life, 119e-4
 in Gaucher disease, 432e-5
 in malabsorption syndromes, 1945
 in metastatic bone disease, 119e-4
 in sickle cell anemia, 634, 635
 treatment of, 61, 119e-4
- Bone sarcoma, **119e-3**
 chondrosarcoma, 101e-6t, **119e-3**
 classification of, 119e-3
 epidemiology of, 119e-3
 Ewing's sarcoma. *See* Ewing's sarcoma
 incidence of, 119e-3
 osteosarcoma, 101e-2t, **119e-3**, 236
 staging of, 119e-3, 119e-3t
- Bone scan, 426e-2–3, 582
- Bone spicules, 206, 206f
- Bone spurs, 2493
- Bordetella* spp., 1021
- Bordetella pertussis*, 145e-2t, 1021–1022. *See also* Pertussis
- Bornholm disease (pleurodynia), 1291
- Boron, 96e-9t
- Borrelia* spp., 150e-1, 150e-8, 1146, 1146t. *See also* Relapsing fever
- Borrelia burgdorferi*, 145e-3, 1149–1150, 1561. *See also* Lyme borreliosis (Lyme disease)
- BOR (branchio-oto-renal) syndrome, 222t
- Bortezomib
 action and targets of, 102e-5t, 102e-6, 103e-18t, 103e-19
 adverse effects of, 103e-18t, 103e-19, 607, 607t, 716–717, 2686t
 for amyloidosis, 723
 for kidney transplant rejection, 1829
 for mantle cell lymphoma, 704
 for multiple myeloma, 102e-5t, 102e-6, 103e-19, 716–717
 for Waldenström's macroglobulinemia, 718
- Bosentan
 for high-altitude pulmonary edema, 476e-3
 for ischemic ulcers, 2164
 for pulmonary arterial hypertension, 1513, 1659–1660, 1660t, 2164
- Boston exanthem, 1292
- Bosutinib
 action and targets of, 102e-3, 102e-5t, 103e-17t
 adverse effects of, 103e-17t, 692
 for CML, 691–692, 691t
 resistance to, 103e-16
- Botflies, 2746–2747
- Botryomycosis, 1087, 1090
- Botswana, 13e-6–7
- Botulinum antitoxin, 989
- Botulinum toxin
 for achalasia, 1904
 for anal fissure, 1978
 as bioterrorism agent, 261e-8, 988. *See also* Botulism
 botulism and, 988
 for dystonia, 2621
 for essential tremor, 2620
 for gastroparesis, 261
 for hemifacial spasm, 2648
 for hyperhidrosis, 2643
 for ischemic ulcers, 2164
 for migraine prevention, 2594t
 for tics, 2623
- Botulinum toxoid, 261e-9
- Botulism, **987**
 antitoxin, 989
 in bioterrorism, 261e-8
 clinical features of, 261e-5t, **988**
 neurologic, 261e-9, 1784, 2642, 2703
 diagnosis of, 261e-5t, 988–989
 differential diagnosis of, 989
 diplopia in, 208
 epidemiology of, 987–988
 etiology of, 987
 food-borne, 987–988
 global considerations in, 987
 iatrogenic, 988
 infant, 987, 988, 1784
 inhalational, 988
 intentional, 988
 intestinal, 987, 988
 notification of, 989
 pathogenesis of, 987, 2703
 prevention of, 261e-5t, 261e-9, 989
 treatment of, 261e-5t, 261e-9, 989, 2703
 wound, 987, 988, 1784
- Bouba. *See* Yaws
- Bouchard's nodes, 2226f
- Bound morphemes, 178
- Bourneville's disease. *See* Tuberous sclerosis (Bourneville's disease)
- Boutonneuse fever (Mediterranean spotted fever), 128t, 782, 1155t, 1157
- Boutonnière deformity, 2136
- Bovine papular stomatitis, 220e-1t
- Bovine spongiform encephalopathy (BSE), 453e-1t, 453e-2
- Bowel obstruction. *See* Intestinal obstruction
- Bowen's disease, 351, 353t, 501
- Bowlegs, 2221, 2228, 2228f
- Bowman's capsule, 332e-1
- Box jellyfish envenomation, 2739, 2741–2742
- Bpi (bactericidal/permeability-increasing protein), 372e-24t
- Brachial neuritis, 122
- Brachial plexopathy
 imaging in, 441e-30–31f
 immune-mediated, 2692
 neoplastic, 618, 2692–2693
- Brachial plexus, 122, 2693, 2694f
- Brachytherapy
 for cholangiocarcinoma, 553
 definition of, 103e-4
 for prostate cancer, 584
 for soft tissue sarcoma, 119e-2
- Bradyarrhythmias
 with asystole, 1769f
 in AV conduction block. *See* Atrioventricular (AV) conduction block
 etiology of, 763t, 1466, 1470
 junctional bradycardia, 278e-3f
 mechanism of, 1466, 1466f, 1467f
 pacemaker for, 273e-7
 relative bradycardia, 126
 in SA node dysfunction. *See* Sinoatrial (SA) node disease/dysfunction
 syncope in. *See* Cardiac syncope
- Bradykinesia, 154, 2609
- Bradykinin, 88f
- Bradyrhizobium enterica*, 772
- BRAF gene mutations
 in colorectal cancer, 101e-1f
 as drug target, 32, 101e-8, 102e-6, 103e-19
 in hairy cell leukemia, 135e-2, 706
 in lung cancer, 507t, 509, 509f, 521
 in melanoma, 496, 499
 in thyroid cancer, 2304, 2305t
 tumors associated with, 101e-2t
- BRAF inhibitors
 action of, 102e-3, 103e-19
 adverse effects of, 103e-17t, 380
 for melanoma, 499, 501
- Brain
 atrophy of, 75–76, 76f
 cerebral hemispheres, 176f, 2572f, 2573f, 2574f
 coronal section of, 2572f
 gut microbiota and, 86e-7–8
 inferior aspect of, 2575f
 lateral aspect of, 2573f
 medial aspect of, 2574f
 metastases to, 1792
- Brain abscess, **900**
 anaerobic bacterial, 1097–1098
 approach to the patient, 883–884, 884–885f
 in cancer patient, 488, 488t
 clinical features of, 783, 901
 definition of, 900
 diagnosis of, 440e-5f, 901, 902f
 differential diagnosis of, 902
 epidemiology of, 900
 etiology of, 780t, 900–901, 1097–1098
 global considerations in, 900
 histopathology of, 901
 nodocardial, 1085, 1085f, 1087
 pathogenesis of, 901
 prognosis of, 902
 treatment of, 780t, 902
- Brain biopsy, 175, 386e-6f, 895
- Brain death, 442e-2, 1735, 1776
- Brain-derived neurotrophic factor (BDNF), 444e-7t
- Brain drain, 13–14
- Brain edema, 1777
- Brainerd diarrhea, 267
- BRAIN (Brain Research through Advancing Innovative Neurotechnologies) Initiative, 444e-12–13
- Brain injury
 post-cardiac bypass, 463e-2–3, 463e-2f
 post-solid organ transplantation, 463e-3
 stem cell therapy in, 90e-3
 traumatic. *See* Head injury